Literature DB >> 15281663

Evaluation of a technique of inducing hypertensive renal insufficiency in cats.

Sheerin Mathur1, Cathy A Brown, Ursula M Dietrich, John S Munday, Melvin A Newell, Suzanne E Sheldon, Leslie M Cartier, Scott A Brown.   

Abstract

OBJECTIVE: To compare 2 techniques of inducing combined renal insufficiency and systemic hypertension in cats. ANIMALS: 22 cats 6 to 12 months of age. PROCEDURES: Cats were randomly assigned to 1 of 3 groups. Control (C) group cats had 2 intact kidneys, remnant kidney (RK) group cats underwent unilateral partial renal infarction and contralateral nephrectomy, and remnant-wrap (W) group cats underwent unilateral partial renal infarction and partial abtation and wrapping of the contralateral kidney. Systemic arterial blood pressure (BP) was measured continuously by use of implanted radiotelemetric devices. Renal function was assessed via determination of glomerular filtration rate, measurement of serum creatinine and BUN concentrations, and determination of urine protein-to-creatinine ratio (UP/C). Serum aldosterone concentration and plasma renin activity were measured on day 75.
RESULTS: Systolic BP was significantly higher in groups RK and W than in group C, and systolic BP was significantly higher in group W than in group RK. Serum aldosterone concentration and plasma renin activity were significantly higher in group W, compared with groups C and RK. Glomerular filtration rate was significantly lower in groups RK and W, compared with group C. Histologic indices of renal injury and UP/C were significantly higher in group W, compared with groups C and RK. CONCLUSIONS AND CLINICAL RELEVANCE: Hypertensive renal insufficiency in group W was characterized by marked sustained systemic hypertension, decreased renal function, proteinuria, activation of the renin-angiotensin-aldosterone axis, and renal structural injury. Results support the hypothesis that marked systemic hypertension, activation of the renin-angiotensin-aldosterone axis, and proteinuria may damage the kidney of cats with preexisting renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15281663     DOI: 10.2460/ajvr.2004.65.1006

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  Insights into the development and treatment of cardiovascular disease: a role for animal models.

Authors:  Cecil S Thompson
Journal:  Open Cardiovasc Med J       Date:  2010-11-26

2.  Relationship between indirect blood pressure and various stages of chronic kidney disease in cats.

Authors:  Yasutomo Hori; Yasuhiro Heishima; Yohei Yamashita; Noriko Isayama; Nobuyuki Kanno; Kensuke Nakamura; Masayuki Iguchi; Toshiki Ibaragi; Hideyuki Onodera; Yoshitaka Aramaki; Atsushi Hirakawa; Shigeki Yamano; Michio Katagi; Akihito Kitade; Tamotsu Sawada
Journal:  J Vet Med Sci       Date:  2018-01-03       Impact factor: 1.267

3.  Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial.

Authors:  Amanda E Coleman; Scott A Brown; Anne M Traas; Lawrence Bryson; Tanja Zimmering; Alicia Zimmerman
Journal:  J Vet Intern Med       Date:  2019-03-09       Impact factor: 3.333

Review 4.  Vitamin D Metabolism and Its Role in Mineral and Bone Disorders in Chronic Kidney Disease in Humans, Dogs and Cats.

Authors:  Fernanda C Chacar; Márcia M Kogika; Rafael V A Zafalon; Marcio A Brunetto
Journal:  Metabolites       Date:  2020-12-04

5.  Characterization of the intrarenal renin-angiotensin system in cats with naturally occurring chronic kidney disease.

Authors:  Bianca N Lourenço; Amanda E Coleman; Roy D Berghaus; Jaime L Tarigo; Chad W Schmiedt; Scott A Brown
Journal:  J Vet Intern Med       Date:  2022-01-19       Impact factor: 3.333

6.  The Effect of Chinese rhubarb, Rheum officinale, with and without benazepril on the progression of naturally occurring chronic kidney disease in cats.

Authors:  A S Hanzlicek; C J Roof; M W Sanderson; G F Grauer
Journal:  J Vet Intern Med       Date:  2014-04-28       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.